AI ML Collaboration Strong partner potential with LG Chem for AI/ML designed tumour-targeting antibodies and multi-year research collaborations, presenting an opportunity to position AI-driven discovery services and platform licensing to expand joint development.

Preclinical Pipeline Active preclinical data for LGTX-101 Nectin-4 x CD3 T-cell engager signals near-term engagement for biotech partners seeking novel immunotherapies, offering co-development or co-commercialization discussions and technology licensing.

Platform Advantage EVA platform combines AI, robotics, and synthetic biology across modalities, enabling scalable antibody design and rapid iteration — a compelling selling point for CROs and pharma seeking efficiency gains and best-in-class candidates.

Strategic Funding Recent investments and strategic collaborations (Sanofi, venture investors, AIM VCT) indicate growing interest and validation, creating openings for additional partnerships, joint ventures, or minority investments to accelerate pipeline milestones.

Funding and Revenue Current revenue at a startup scale with substantial funding runway, suggesting readiness for milestone-driven deals, licensing agreements, and service-based engagements with larger biopharma players seeking innovative antibody discovery capabilities.